X4 Pharmaceuticals (XFOR)
(Real Time Quote from BATS)
$1.28 USD
+0.02 (1.67%)
Updated Apr 23, 2024 02:32 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for X4 Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 114 | 122 | 82 | 79 | 126 |
Receivables | 1 | 1 | 1 | 1 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 6 | 5 | 4 | 1 |
Total Current Assets | 122 | 129 | 88 | 83 | 129 |
Net Property & Equipment | 1 | 1 | 2 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 17 | 17 | 27 | 27 |
Deposits & Other Assets | 1 | 1 | 2 | 3 | 2 |
Total Assets | 147 | 156 | 117 | 123 | 161 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 8 | 4 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 1 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 12 | 8 | 8 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 23 | 22 | 14 | 12 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 55 | 32 | 33 | 33 | 20 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16 | 23 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 82 | 53 | 50 | 31 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 529 | 451 | 347 | 267 | 261 |
Retained Earnings | -478 | -377 | -283 | -194 | -132 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 51 | 74 | 64 | 73 | 129 |
Total Liabilities & Shareholder's Equity | 147 | 156 | 117 | 123 | 161 |
Total Common Equity | 51 | 74 | 64 | 73 | 129 |
Shares Outstanding | 167.20 | 121.60 | 24.70 | 16.30 | 12.40 |
Book Value Per Share | 0.31 | 0.61 | 2.61 | 4.47 | 10.42 |
Fiscal Year End for X4 Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 114 | 142 | 141 | 93 |
Receivables | NA | 1 | 0 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 6 | 6 | 4 |
Total Current Assets | NA | 122 | 148 | 148 | 98 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 17 | 17 | 17 | 17 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 147 | 173 | 173 | 124 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 8 | 5 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 1 | 1 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 13 | 16 | 15 | 12 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 23 | 25 | 22 | 19 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 55 | 54 | 32 | 32 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 23 | 49 | 18 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 96 | 106 | 106 | 73 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 529 | 526 | 524 | 452 |
Retained Earnings | NA | -478 | -459 | -456 | -401 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 51 | 68 | 68 | 52 |
Total Liabilities & Shareholder's Equity | NA | 147 | 173 | 173 | 124 |
Total Common Equity | 0 | 51 | 68 | 68 | 52 |
Shares Outstanding | 167.90 | 167.20 | 164.40 | 164.40 | 122.20 |
Book Value Per Share | 0.00 | 0.31 | 0.41 | 0.41 | 0.42 |